Xoma | XOMA - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.81B 13.45B 2025-12
Agenus USD 19.81M 293.94M 2025-12
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Ardelyx USD 120.12M 14.46M 2025-12
aTyr Pharma USD 85.61M 58.67M 2025-12
BioMarin Pharmaceutical USD 676.18M 131.65M 2025-12
Celldex Therapeutics USD 87.27M 511.09M 2025-12
Curis USD -13.99M 7.38M 2025-06
Eli Lilly USD 10.31B 1.09B 2025-12
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Incyte USD 1.12B 3.53B 2025-12
MacroGenics USD 53.32M 13.68M 2025-12
Novartis USD 9.8B 61M 2025-12
Novartis USD 9.8B 23M 2025-12
Pfizer USD 12.91B 79.89B 2025-12
Prothena USD 27.23M 14.95M 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Xoma USD 22.84M 1.67M 2024-09